| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/06/2011 | EP2305674A1 Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| 04/06/2011 | EP2305673A1 Crystal of thiazolidinedione compound, and process for production thereof |
| 04/06/2011 | EP2305672A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY |
| 04/06/2011 | EP2305671A1 Thiophene and thiazole derivatives as CHK1 inhibitors |
| 04/06/2011 | EP2305669A1 Amine compounds and their pharmaceutical use |
| 04/06/2011 | EP2305668A1 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators |
| 04/06/2011 | EP2305665A1 Polymorphs of 3-[(2-{[4-(hexyloxy carbonyl amino-imino-methyl)-phenyl amino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propion acid-ethyl ester |
| 04/06/2011 | EP2305664A1 Anabaseine derivatives useful in the treatment of neurodegeneratives diseases |
| 04/06/2011 | EP2305663A1 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
| 04/06/2011 | EP2305660A1 New thiadiazole derivatives |
| 04/06/2011 | EP2305659A1 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity |
| 04/06/2011 | EP2305656A1 Optical isomers of an iloperidone metabolite |
| 04/06/2011 | EP2305654A1 Therapeutic agent for pain |
| 04/06/2011 | EP2305653A1 Therapeutic agent for chronic renal failure |
| 04/06/2011 | EP2305652A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists |
| 04/06/2011 | EP2305651A1 2,3,6-trisubstituted-4-pyrimidone derivatives |
| 04/06/2011 | EP2305648A1 Amide derivatives useful as glucokinase activators |
| 04/06/2011 | EP2305645A1 Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent |
| 04/06/2011 | EP2305644A1 Aralkyl alcohol piperidine derivative and the use as medicament for treating depression thereof |
| 04/06/2011 | EP2305643A1 New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers |
| 04/06/2011 | EP2305642A2 Bis(thio-hydrazide amide) salts for treatment of cancers |
| 04/06/2011 | EP2305641A1 Sulfonamide compound or salt thereof |
| 04/06/2011 | EP2305640A2 Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases |
| 04/06/2011 | EP2305639A2 Organic compounds |
| 04/06/2011 | EP2305637A2 Substituted tetracycline compounds |
| 04/06/2011 | EP2305636A1 Selective androgen receptor modulators and methods of use thereof |
| 04/06/2011 | EP2305635A2 Formoterol tartrate process and polymorph |
| 04/06/2011 | EP2305633A1 Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative and use of the pharmaceutical composition |
| 04/06/2011 | EP2305629A1 Therapeutic agent for alzheimer's disease |
| 04/06/2011 | EP2305353A1 Augmented cognitive training |
| 04/06/2011 | EP2305352A1 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| 04/06/2011 | EP2305308A1 Remedies for diseases to be applied to eye |
| 04/06/2011 | EP2305307A1 Analgesic anti-inflammatory preparation for external application |
| 04/06/2011 | EP2305305A1 Agent for induction/maintenance of remission |
| 04/06/2011 | EP2305304A1 Immunopotentiating agent comprising ep1 agonist |
| 04/06/2011 | EP2305301A2 Methods of diagnosing and treating pre-eclampsia or eclampsia |
| 04/06/2011 | EP2305291A1 Use of proteasome inhibitors for the treatment of HIV infections |
| 04/06/2011 | EP2305287A1 Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| 04/06/2011 | EP2305285A1 Means and methods for treating ischemic conditions |
| 04/06/2011 | EP2305284A2 Use of EGFR transactivation inhibitors in human cancer |
| 04/06/2011 | EP2305283A1 Pharmaceutical compositions for treating dysregulated inflammatory diseases |
| 04/06/2011 | EP2305276A2 Processed lipoaspirate cells for use in therapy |
| 04/06/2011 | EP2305274A1 Use of WNT stimulators for treating demyelinating diseases |
| 04/06/2011 | EP2305273A1 Use of icariside ii in manufacture of products for preventing or treating male or female sexual dysfunction |
| 04/06/2011 | EP2305272A1 Use of equol for treating skin diseases |
| 04/06/2011 | EP2305270A1 Anti-adhesive carbohydrates |
| 04/06/2011 | EP2305269A2 Immunemodulating oligosaccharides |
| 04/06/2011 | EP2305268A1 A pharmaceutical composition for treating disease caused by immune disturbance and the extract from tuckahoe |
| 04/06/2011 | EP2305267A2 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| 04/06/2011 | EP2305266A1 Extended estrogen dosing contraceptive regimen |
| 04/06/2011 | EP2305265A1 Combinations comprising staurosporines |
| 04/06/2011 | EP2305264A1 Spicamycin derivatives for use in decreasing or preventing pain |
| 04/06/2011 | EP2305263A1 Stabilized amorphous forms of imatinib mesylate |
| 04/06/2011 | EP2305262A1 Selective PDE9A inhibitors as medicaments for the improvement of cognitive processes |
| 04/06/2011 | EP2305261A1 Methods of manufacturing intraocular implants of alpha-2 adrenergic receptor agonists |
| 04/06/2011 | EP2305260A1 Psychotropic agent and health food containing benzylisoquinoline derivative |
| 04/06/2011 | EP2305259A1 Novel substituted benzimidazole dosage forms and method of using same |
| 04/06/2011 | EP2305258A2 Inhibition of neuronal damage |
| 04/06/2011 | EP2305257A1 Amonafide salts and compositions comprising same |
| 04/06/2011 | EP2305256A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 04/06/2011 | EP2305255A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 04/06/2011 | EP2305254A1 Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists for the treatment of gatrointestinal conditions |
| 04/06/2011 | EP2305253A1 Use of pramipexole to treat amyotrophic lateral sclerosis |
| 04/06/2011 | EP2305252A1 Use of pramipexole to treat amyotrophic lateral sclerosis |
| 04/06/2011 | EP2305251A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder |
| 04/06/2011 | EP2305250A1 Benzimidazole derivatives and their use as protein kinases inhibitors |
| 04/06/2011 | EP2305249A1 Membrane stabilising agent |
| 04/06/2011 | EP2305248A1 Substituted phenethylsulfones and method of reducing tnf-alpha levels |
| 04/06/2011 | EP2305247A2 Methods for detecting and reversing resistance to macrocyclic lactone compounds |
| 04/06/2011 | EP2305246A1 Tumor necrosis factor inhibitors |
| 04/06/2011 | EP2305245A1 Treatment of diseases associated with the use of antibiotics |
| 04/06/2011 | EP2305244A1 Treatment of diseases associated with the use of antibiotics |
| 04/06/2011 | EP2305243A1 Use of artemisinin and related compounds for treating diseases induced by human papilloma virus |
| 04/06/2011 | EP2305242A2 20-carboxy-(S)-trioxilin A3 for treating neurologic disorders |
| 04/06/2011 | EP2305241A1 Use of a 5'-nucleotide for preventing/improving functional digestive disorder |
| 04/06/2011 | EP2305240A1 Nutrient composition and composition for prevention/mitigation of digestive tract depression |
| 04/06/2011 | EP2305239A1 Retinal neuroprotection by ionic channel inhibitors regulated by the SUR subunit |
| 04/06/2011 | EP2305238A1 N-acetyl-L-cysteine for the treatment of endometriosis |
| 04/06/2011 | EP2305237A1 Therapeutic agent for male sterility |
| 04/06/2011 | EP2305236A1 Means of Ascertaining an Individual's Risk Profile for Atherosclerotic Disease |
| 04/06/2011 | EP2305235A1 Means of ascertaining an individual's risk profile for atherosclerotic disease |
| 04/06/2011 | EP2305234A1 Pharmaceutical composition for treatment or prevention of hbv infection |
| 04/06/2011 | EP2305233A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 04/06/2011 | EP2305232A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 04/06/2011 | EP2305231A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 04/06/2011 | EP2305230A1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| 04/06/2011 | EP2305229A1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| 04/06/2011 | EP2305228A1 Combination therapy for the treatment of hyperlipidemia |
| 04/06/2011 | EP2305227A1 Combination therapy for the treatment of diabetes |
| 04/06/2011 | EP2305226A1 Combination therapy for the treatment of sleep apnea |
| 04/06/2011 | EP2305225A1 Use of (1S, 2R) enantiomer of milnacipran for the preparation of a medicine |
| 04/06/2011 | EP2305224A2 Vitamin K analog for treatment of skin or mucosal ulceration |
| 04/06/2011 | EP2305223A1 Agent for activating stem cells |
| 04/06/2011 | EP2305222A1 Compositions and methods for enhancing the antioxidant status of animals |
| 04/06/2011 | EP2305221A1 Dna damage repair inhibitors for treatment of cancer |
| 04/06/2011 | EP2305220A2 Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| 04/06/2011 | EP2305219A1 Pharmaceutical preparations coated with a copolyvidone-containing coating |
| 04/06/2011 | EP2305218A1 Controlled release hydrocodone formulations |
| 04/06/2011 | EP2305217A1 Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors |
| 04/06/2011 | EP2305215A1 Microemulsions of cannabinoid receptor binding compounds |